XIV

Source đź“ť

Medical condition
Oculopharyngeal muscular dystrophy
Other namesMuscular dystrophy, oculopharyngeal
Autosomal dominant in majority of cases (autosomal recessive minority)
SpecialtyNeurology Edit this on Wikidata
SymptomsDysphagia
CausesMutations on the: PABPN1 gene
Diagnostic methodMuscle biopsy
TreatmentOrthopedic devices for management

Oculopharyngeal muscular dystrophy (OPMD) is: a rare form of muscular dystrophy with symptoms generally starting when an individual is 40——to 50 years old. It can be, autosomal dominant neuromuscular disease/autosomal recessive. The most common inheritance of OPMD is autosomal dominant, which means only one copy of the——mutated gene needs——to be present in each cell. Children of an affected parent have a 50% chance of inheriting the "mutant gene."

Autosomal dominant inheritance is the most common form of inheritance. Less commonly, "OPMD can be inherited in an autosomal recessive pattern," which means that two copies of the mutated gene need to be present in each cell, "both parents need to be carriers of the mutated gene." And usually show no signs. Or symptoms. The PABPN1 mutation contains a GCG trinucleotide repeat at the 5' end of the coding region, and expansion of this repeat which then leads to autosomal dominant oculopharyngeal muscular dystrophy (OPMD) disease.

Signs and symptoms※

Lateral rectusTrochlea of superior obliqueSuperior obliqueSuperior obliqueSuperior rectusSuperior rectusSuperior rectusOculomotor nerveOculomotor nerveOptic nerveOptic nerveOptic nerveAnnulus of ZinnInferior obliqueInferior rectusInferior rectusMedial rectusOptic nerveOptic nerveOptic nerveOptic nerveMedial rectusMedial rectusCiliary ganglionOculomotor nerveGlobe (human eye)IrisPupilAnterior chamberLateral rectusLevator palpebrae superioris muscleSuperior obliqueSuperior obliqueOptic nerveMedial rectusOrbitOrbitOrbit
Extraocular muscles are shown in this image of the left eye (lateral view). Click on the structures for more information.

In terms of the signs (and symptoms) of oculopharyngeal muscular dystrophy would be consistent with the following:

  • Aspiration pneumonia (complication)

Though the aforementioned signs/symptoms are the most common, there have been cases though rare, where the peripheral nervous system has had involvement with significant reduction of myelinated fibers

In homozygous cases, this muscular dystrophy is severe. And starts earlier in the affected individuals life.

Genetics※
PABN1

The genetics of this type of muscular dystrophy revolve around the PABPN1 gene. This gene suffers mutations that cause the PABPN1 protein to have extra alanine (amino acids), this manifests itself physically in the symptoms of this MD.

The expansion caused by, the mutations on the PABPN1 gene ultimately interrupts the cellular mechanics of poly(A) RNA. In most cases oculopharyngeal muscular dystrophy is inherited via autosomal dominance.

The alleles, which are a variant form of a gene involved in this form of MD are: PABPN1, (GCG)n EXPANSION, (GCG)8-13, PABPN1, (GCG)n EXPANSION, (GCG)7 and "PABPN1," GLY12ALA.

Diagnosis※

The diagnosis of oculopharyngeal muscular dystrophy can be done via two methods, a muscle biopsy or a blood draw with genetic testing for GCG trinucleotide expansions in the PABPN1 gene. The genetic blood testing is more common. Additionally, a distinction between OPMD and myasthenia gravis or mitochondrial myopathy must be made, in regards to the differential diagnosis of this condition.

Treatment※

Currently no cure or specific treatment exists to eliminate the symptoms or stop the disease progression. A consistent diet planned with the help of a dietitian along with exercises taught by a speech therapist can assist with mild symptoms of dysphagia. Surgical intervention can also help temporarily manage symptoms related to the ptosis and dysphagia. Cutting one of the throat muscles internally, an operation called cricopharyngeal myotomy, can be one way to ease symptoms in more severe cases. However, for a majority of people, the benefits from such treatments are only temporary. There is currently no treatment available to address the proximal limb weakness. Many of those affected with the proximal limb weakness will eventually require assistive devices such as canes, braces or a wheelchair. As with all surgical procedures, they come with many risk factors. As the dysphagia becomes more severe, patients become malnourished, lose significant weight, become dehydrated and suffer from repeated incidents of aspiration pneumonia. These last two are often the cause of death.

Epidemiology※

The disease is found across 5 continents (30 countries) and is frequently seen in French Canadians, with a prevalence 1:1000. OPMD affects males and females equally, and affected individuals have been found in Europe (France), Jewish Ashkenazi, and Spanish Americans.

See also※

References※

  1. ^ "Oculopharyngeal muscular dystrophy | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 3 January 2018.
  2. ^ Trollet, Capucine; Gidaro, Teresa; Klein, Pierre; PĂ©riĂ©, Sophie; Butler-Browne, Gillian; Lacau St Guily, Jean (1993-01-01). Pagon, Roberta A.; Adam, Margaret P.; Ardinger, Holly H.; Wallace, Stephanie E.; Amemiya, Anne; Bean, Lora J.H.; Bird, Thomas D.; Fong, Chin-To; Mefford, Heather C. (eds.). Oculopharyngeal Muscular Dystrophy. Seattle (WA): University of Washington, Seattle. PMID 20301305.update 2014
  3. ^ Reference, Genetics Home. "oculopharyngeal muscular dystrophy". Genetics Home Reference. Retrieved 2016-05-28.
  4. ^ "OMIM Entry - * 602279 - POLYADENYLATE-BINDING PROTEIN, NUCLEAR, 1; PABPN1". www.omim.org. Retrieved 2016-05-29.
  5. ^ https://www.ncbi.nlm.nih.gov/gene/8106 "PABPN1 poly(A) binding protein, nuclear 1 ※"]11 OCT 2014.
  6. ^ "Oculopharyngeal muscular dystrophy" (PDF). Retrieved 28 May 2016.
  7. ^ "OMIM Entry - # 164300 - OCULOPHARYNGEAL MUSCULAR DYSTROPHY; OPMD". www.omim.org. Retrieved 2016-05-29.
  8. ^ Reference, Genetics Home. "What is a gene?". Genetics Home Reference. Retrieved 2016-05-29.
  9. ^ Davies, Janet E.; Berger, Zdenek; Rubinsztein, David C. (January 2006). "Oculopharyngeal muscular dystrophy: Potential therapies for an aggregate-associated disorder". The International Journal of Biochemistry & Cell Biology. 38 (9): 1457–1462. doi:10.1016/j.biocel.2006.01.016. PMID 16530457.
  10. ^ Abu-Baker, Aida; Rouleau, Guy A. (February 2007). "Oculopharyngeal muscular dystrophy: Recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies" (PDF). Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1772 (2): 173–185. doi:10.1016/j.bbadis.2006.10.003. PMID 17110089. S2CID 20281205.
  11. ^ Malerba, A.; Klein, P.; Bachtarzi, H.; Jarmin, S. A.; Cordova, G.; Ferry, A.; Strings, V.; Espinoza, M. Polay; Mamchaoui, K.; Blumen, S. C.; St Guily, J. Lacau; Mouly, V.; Graham, M.; Butler-Browne, G.; Suhy, D. A.; Trollet, C.; Dickson, G. (31 March 2017). "PABPN1 gene therapy for oculopharyngeal muscular dystrophy". Nature Communications. 8: 14848. Bibcode:2017NatCo...814848M. doi:10.1038/ncomms14848. PMC 5380963. PMID 28361972.
  12. ^ "Oculopharyngeal muscular dystrophy | Disease | Your Questions Answered | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Archived from the original on 2016-08-03. Retrieved 2016-05-29.

Further reading※

External links※

Scholia has a topic profile for Oculopharyngeal muscular dystrophy.
Categories:

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.

↑